◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Alfresa Holdings Corporation (2784)

Name: Alfresa Holdings Corporation（2784）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

Healthcare · ウォール街（米国） · 最終更新: 2026-09-21

Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. The company operates through Wholesale of Prescription Drugs and Related Products, Wholesale of Self-Medication Products, Manufacturing of Pharmaceuticals and Related Products, and Pharmacy and Related Businesses segments.

主要指標

時価総額: JPY 413 billion
売上高（2026-03-31 期末の会計年度）: JPY 3.10T
当期純利益: JPY 41.7B
売上総利益率: 7.0%
純利益率: 1.3%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
売上高合計	JPY 3.10T	JPY 2.96T	JPY 2.86T	JPY 2.70T	—
売上総利益	JPY 217.9B	JPY 213.9B	JPY 206.4B	JPY 192.1B	—
営業利益（EBIT）	JPY 36.2B	JPY 38.1B	JPY 38.5B	JPY 30.1B	—
当期純利益	JPY 41.7B	JPY 27.4B	JPY 29.6B	JPY 25.8B	—

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は 2784 のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/2784

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.